Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMROSE: AZD3470 Monotherapy and in Combination With Anticancer Agents in Advanced/Metastatic Solid Tumors That Are MTAP Deficient
NCT06130553Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of AZD3470 in solid tumor (3 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of adverse events and serious adverse events, Incidence of dose-limiting toxicities and 1 more. Started Jan 2024; status: recruiting.
02
Drugs
AZD3470
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06130553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06130553.